Pulmonary complications of HIV infection

Current Opinion in Pulmonary Medicine

Volumn 3, Issue 2, 1997, Pages 151-158

  Schneider, Roslyn F ^a   Rosen, Mark J ^a  

^a BETH ISRAEL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AIDS RELATED COMPLEX; BACTERIAL PNEUMONIA; HUMAN; LUNG TUBERCULOSIS; PNEUMOCYSTIS PNEUMONIA; RESPIRATORY TRACT INFECTION; REVIEW;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; HUMANS; PNEUMONIA, BACTERIAL; PNEUMONIA, PNEUMOCYSTIS; RESPIRATORY TRACT INFECTIONS; TUBERCULOSIS, PULMONARY;

EID: 0031087953     PISSN: 10705287     EISSN: None     Source Type: Journal    
DOI: 10.1097/00063198-199703000-00012     Document Type: Article

References (73)

1. Mann J, Tarantolo DM, Netter TW (eds): AIDS in the World. Cambridge: Harvard University Press; 1992.
2. Centers for Disease Control and Prevention: First 500,000 AIDS cases: United States, 1995. MMWR Morb Mortal Wkly Rep 1995, 44:849-853. A description of the epidemiologic characteristics of the first 500,000 cases of AIDS, highlighting the changes that have occurred since the epidemic began. The greatest proportionate increases in the incidence of AIDS are in blacks and Hispanics, and in the southern and midwestern United States. The proportion has increased among women, heterosexuals, and injecting drug users and has decreased in homosexual or bisexual men and among whites.
3. Centers for Disease Control and Prevention: Update: Mortality attributable to HIV infection among persons aged 25-44 years: United States, 1994. MMWR 1996, 45:121-125. In 1994, HIV infection was the eighth leading cause of death overall and the leading cause of death in persons aged 25 to 44 years. There was a disproportionate rise in the death rate among black men and women.
4. O'Brien TR, Blattner WA, Waters D, Eyster E, Hilgartner MW, Cohen AR, Luban N, Hatzakis A, Aledort LM, Rosenberg PS, Miley WH, Kroner BL, Goedert JJ, for the Multicenter Hemophilia Cohort Study: Serum HIV-1 RNA levels and time to development of AIDS in the Multicenter Hemophilia Cohort Study. JAMA 1996, 276:105-110. This study validates the measurement of HIV-1 load in serum as a predictor of progression of HIV infection. From 1979 to 1995, serum specimen: from 165 persons with hemophilia and HIV-1 infection were stored. At ten years after sero-conversion, 72% of those who had 100,000 copies of HIV-1 RNA/mL, measured 12 to 36 months after seroconversion, had AIDS, compared with 52% in those with 10,000 to 99,999, 22% in those with 1000 to 9999, and 0% in those with fewer than 1000 copies of HIV-1 RNA/mL.
5. Selwyn PA: HIV therapy in the real world [editorial]. AIDS 1996, 10:1591-1593.
6. Fauci AS: AIDS in 1996; much accomplished, much to do [editorial]. JAMA 1996, 276:155-156.
7. Schneider RF, Hansen NI, Rosen MJ, Kvale PA, Fulkerson WJ, Goodman P, Meiselman L, Glassroth J, Reichman LB, Wallace JM, Hopewell PC, and the Pulmonary Complications of HIV Infection Study Group: Lack of utility of radiographic screening for pulmonary diseases in asymptomatic HIV-infected adults. Arch Intern Med 1996, 156:191-195.
8. 6/L were studied. The incidence of secondary PCP decreased between the periods of 1989 to 1992 and 1993 to 1995, largely due to the use of TMP-SMZ prophylaxis. However, PCP is still common, with a probability of occurring in approximately 20% of the cohort during 3 years of follow-up.
9. Daley CL, Mugusi F, Chen LL, Schmidt DM, Small P, Bearer E, Aris E, Mtoni IM, Cegielski JP, Lallinger G, Mbaga I, Murray JF: Pulmonary complications of HIV infection in Dar es Salaam, Tanzania. Am J Respir Crit Care Med 1996, 154:105-10.
10. Enger C, Graham N, Peng Y, Chmiel JS, Kingsley LA, Detels R, Muñoz A: Survival from early, intermediate and late stages of HIV infection. JAMA 1996, 275:1329-1334. In the Multicenter AIDS Cohort Study, the probability of surviving for 2.5 years improved after 1993 in patients with intermediate- and late-stage HIV infection.
11. Chan IF, Neaten JD, Saravolatz LD, Crane LR, Osterberger J, for the Community Programs for Clinical Research on AIDS: Frequencies of opportunistic diseases prior to death among HIV-infected persons. AIDS 1995, 9:1145-1151. AIDS-defining events before death were studied in a group of 1883 persons who died between 1990 and 1994 while enrolled in an ongoing population-based study. The most common events were PCP, MAC, wasting syndrome, bacterial pneumonia, cytomegalovirus, and candidiasis.
12. Selik RM, Chu SY, Ward JW: Trends in infectious diseases and cancers among persons dying of HIV infection in the United States from 1987-1992. Ann Intern Med 1995, 123:933-936. Death certificates of persons with HIV infection were studied from 1987 to 1992. The percentages of deaths due to PCP, cryptococcosis, and candidiasis decreased, whereas there were increases in deaths due to nontuberculous mycobacteriosis, cytomegalovirus, bacterial septicemia, non-Hodgkin's lymphoma, tuberculosis, bacterial pneumonia, progressive multifocal leukoencephalopathy, cryptosporidiosis, and isosporiasis.
13. 6/L, respectively.
14. Jordens JA, Paul J, Bates J, Beaumont C, Kimari J, Gilks C: Characterization of Streptococcus pneumoniae from human immunodeficiency virus-seropositive patients with acute and recurrent pneumonia. J Infect Dis 1995, 172:983-987.
15. Paul J, Kimari J, Gilks CF: Streptococcus pneumoniae resistant to penicillin and tetracycline associated with HIV seropositivity. Lancet 1995, 346:1034-1035.
16. Moritz F, Martin E, Lemeland JF, Bonmarchand G, Leroy J, Escande F: Fatal Pasteurella bettyae pleuropneumonia in a patient infected with human immunodeficiency virus. Clin Infect Dis 1996, 22:591-2.
17. Furman AC, Jacobs J, Sepkowitz KA: Lung abscess in patients with AIDS. Clin Infect Dis 1996, 22:81-85.
18. Rodero FG, Ortiz de la Tabla V, Martinez C, del Mar Masiá M, Chiner E, Calpe JL: Legionnaires' disease in patients infected with human immunodeficiency virus [letter]. Clin Infect Dis 1995, 21:712-713.
19. Katapadi K, Pujol F, Vuletin JC, Katapadi M, Pachter BR: Pulmonary botryomycosis in a patient with AIDS. Chest 1996, 109:276-278.
20. Comandini UV, Massetti AP, Marchese R, Zaccarelli M, Vullo V, Delia S: Chlamydia pneumoniae seroprevalence among HIV-1 infected and uninfected people with known HIV risk factors. AIDS 1996, 10:1543-1547.
21. Meynard JL, Barbut F, Blum BL, Guiguet M, Chouaid C, Meyohas MC, Picard O, Petit JC, Frottier J: Risk factors for isolation of Streptococcus pneumoniae with decreased susceptibility to penicillin G from patients infected with human immunodeficiency virus. Clin Infect Dis 1996, 22:437-440.
22. Gallant JE, Ko AH: Cavitary pulmonary lesions in patients infected with human immunodeficiency virus. Clin Infect Dis 1996, 22:671-682.
23. Sutor G-C, Fibich C, Kirschner P, Kuske M, Schmidt RE, Schedel I, Deicher H: Poststenotic cavitating pneumonia due to Rhodococcus equi in HIV infection. AIDS 1996, 10:339-351.
24. Ahmed F, Steinhoff MC, Rodriguez-Barradas MC, Hamilton RG, Musher DM, Nelson KE: Effect of human immunodeficiency virus type 1 infection on the antibody response to a glycoprotein conjugate pneumococcal vaccine: results from a randomized trial. J Infect Dis 1996, 173:83-90.
25. Malin AS, Gwanzura LKZ, Klein S, Robertson VJ, Musvaire P, Mason PR: Pneumocystis carinii pneumonia in Zimbabwe. Lancet 1995, 346:1258-1261. Previous reports indicated that PCP is relatively rare in Africa. This study states that the nuber of cases in Zimbabwe is increasing.
26. Keely SP, Baughman RP, Smulian AG, Dohn MN, Stringer JR: Source of Pneumocystis carinii in recurrent episodes of pneumonia in AIDS patients. AIDS 1996, 10:881-888. Genotypic evidence from studies of BAL specimens of persons with PCP suggests that recurrent episodes of PCP are most likely due to new infections rather than reactivation of latent previously including organisms.
27. Kuhlman JE: Pneumocystic infections: the radiologist's perspective. Radiology 1996, 198:623-635. This is an excellent review of the radiographic findings of PCP, and a well-referenced review of the literature.
28. Chouaid C, Housset B, Lebeau: Cost-analysis of four diagnostic strategies for Pneumocystis carinii pneumonia in HIV-infected subjects. Eur Respir J 1995, 8:1554-1558.
29. Fraser JL, Lilly C, Israel E, Hulme P, Hanff PA: Diagnostic yield of bronchoalveolar lavage and bronchoscopic lung biopsy for detection of Pneumocystis carinii. Mayo Clin Proc 1996, 71:1025-1029. Twenty-one patients with PCP had BAL fluid analyzed with P. carinii-specific immunofluorescent monoclonal antibody reagent, and transbronchial biopsy specimens stained with Grocott methenamine silver nitrate. The yield of BAL was 95%, and the yield of transbronchial biopsy was 43%. Transbronchial biopsy was diagnostic for PCP in only one patient with a negative BAL.
30. Salzman SH, Bernstein LE, Villamena PC, Schneider RF, Mayo PH, Rosen MJ: Bronchoscopic lung biopsy improves the diagnostic yield of bronchoscopy in patients with known or suspected HIV infection. J Bronchol 1996, 3:88-95.
31. 2 less than 45 mm Hg.
32. Young K-T, Chan M, Chan CKN: The safety of IV pentamidine administered in an ambulatory setting. Chest 1996, 110:136-140.
33. Ioannidis JP, Cappelleri JC, Skolnik PR, Lau J, Sacks HS: A meta-analysis of the relative efficacy and toxicity of Pneumocystis carinii prophylactic regimens. Arch Intern Med 1996, 156:177-188. In 35 randomized studies that involved more than 6500 patients and that compared different regimens of PCP prophylaxis and used an intention-to-treat analysis, TMP-SMZ was the best regimen at any of the doses given (one double-strength tablet daily, one double-strength tablet three times weekly and one single-strength tablet daily). Dapsone and aerosolized pentamidine were equally effective for PCP prophylaxis, and dapsone and TMP-SMZ were equally effective for toxoplasmosis prophylaxis. Dapsone, 100 mg daily, was more effective but not as well tolerated as 100 mg twice weekly. Pentamidine may be significantly more effective at a dose of 300 mg twice monthly rather than once monthly.
34. Beumont MG, Graziani A, Ubel PA, MacGregor RR: Safety of dapsone as Pneumocystis carinii pneumonia prophylaxis in human immunodeficiency virus-infected patients with allergy to trimethoprim/sulfamethoxazole. Am J Med 1996, 100:611-616. In 75 patients with previous reactions to TMP-SMZ including rash, fever, neutropenia, nausea, vomiting, anemia, or elevated liver chemistries, only five (7%) developed the same intolerance to dapsone, but these reactions were not attributed to dapsone.
35. Barber BA, Pogrom PS, High KP: Clindamycin/primaquine as prophylaxis for Pneumocystis carinii pneumonia. Clin Infect Dis 1996, 23:718-722. Clindamycin-primaquine was less effective than TMP-SMZ or dapsone in preventing PCP in this study of 206 patients.
36. Antinori A, Murri R, Ammassari A, De Luca A, Linzalone A, Cingolani A, Damiano F, Maiuro G, Vecchiet J, Scoppettuolo G, Tamburrini E, Ortona L: Aerosolized pentamidine, cotrimoxazole and dapsone-pyrimethamine for primary prophylaxis of Pneumocystis carinii pneumonia and toxoplaxmic encephalitis. AIDS 1995, 9:1343-1350. Intermittent TMP-SMZ was more effective than dapsone, 100 mg weekly, with pyrimethamine, 25 mg twice weekly. Intermittent TMP-SMZ and aerosolized pentamidine, 300 mg monthly, were equally effective in the primary prophylaxis of PCP.
37. Rizzardi GP, Lazzarin A, Musicco M, Frigerio D, Maillard M, Lucchini M, Moroni M, and the Italian PCP Study Group: Better efficacy of twice-monthly aerosolised pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with AIDS: An Italian multicentric randomised controlled trial. J Infect 1995, 31:99-105.
38. Thea DM, Lambert G, Weedon J, Matheson PB, Abrams EJ, Bamji M, Straus WL, Thomas PA, Krasinski K, Heagarty M, and the New York City Perinatal HIV Transmission Collaborative Study Group: Benefit of primary prophylaxis before 18 months of age in reducing the incidence of Pneumocystis carinii pneumonia and early death in a cohort of 112 human immunodeficiency virus-infected infants. Pediatrics 1996, 97:59-64. Among infants enrolled in the New York City Perinatal HIV Transmission Collaborative Study, 25 percent of those who did not use prophylaxis developed PCP during the 1st year of follow-up. The relative risk associated with no PCP prophylaxis was 4.4.
39. Shafer RW, Edlin BR: Tuberculosis in patients infected with human immunodeficiency virus: perspective on the past decade. Clin Infect Dis 1996, 22:683-704. This is an excellent review of the pathogenesis, epidemiology, clinical presentation, and treatment of tuberculosis in patients with HIV infection.
40. Triol I, Schwoebel V, Delmas M-C, Pinget R, Laporte A, Brunet J-B: Factors associated with tuberculosis at AIDS diagnosis in France. AIDS 1996, 10:223-228.
41. Sudre P, Hirschel B, Toscani L, Ledergerber B, Rieder HL, and the Swiss HIV Cohort Study: Risk factors for tuberculosis among HIV-infected patients in Switzerland. Eur Respir J 1996, 9:279-283.
42. Barnes PF, Silva C, Otaya M: Testing for human immunodeficiency virus infection in patients with tuberculosis. Am J Respir Crit Care Med 1996, 153:1448-1450. In 183 patients with tuberculosis and no history of HIV infection, 33 (18%) were found to be infected with HIV. At least one high-risk behavior for HIV infection was identified in 68% of the patients with tuberculosis, most often related to heterosexual contact (prostitute contact or multiple partners). Detailed study interviews identified risk factors in 30 of the 33 patients with HIV infection, but the medical record documented risk factors in less than half, which supports testing all patients with tuberculosis for HIV infection.
43. + lymphocytes and lower steady-state mRNA levels of gamma interferon. Interleukin-8, a cytokine that promotes cellular recruitment, is released in both groups when focal disease is present.
44. Chin DP, Osmond D, Page-Shafer K, Glassroth J, Rosen MJ, Reichman LB, Kvale PA, Wallace JM, Poole WK, Hopewell PC, and the Pulmonary Complications of HIV Infection Study Group: Reliability of anergy skin testing in persons with HIV infection. Am J Respir Crit Care Med 1996, 153:1982-1984. In a cohort of HIV-infected persons studied prospectively, the results of standard anergy testing were highly variable. Thirty percent of subjects initially classified as being anergic had positive reactions to mumps or Candida species antigens 1 year later. Cutaneous reactivity control antigens is also an unreliable indicator of a true negative tuberculin test because 39% of persons with a positive tuberculin test that later became negative (false-negative results) still reacted to mumps antigen. The authors suggest that the results of anergy testing should not be used to make clinical decisions on individual patients.
45. Janis EM, Allen DW, Glesby MJ, Carey LA, Mundy LM, Gopalan R, Chaisson RE, the Longscope firm of the Osler medical housestaff, Baltimore, Maryland: Tuberculin skin test reactivity, anergy, and HIV infection in hospitalized patients. Am J Med 1996, 100:186-192.
46. Schoch OD, Rieder HL: Characteristics of sputum smear-positive tuberculosis patients with and without HIV infection in Zimbabwe. Eur Respir J 1996, 9:284-287. Of 196 patients with sputum smears positive for AFB, 127 (65%) were HIV infected. HIV-infected patients had a higher rate of sexually transmitted diseases and herpes zoster than non HIV-infected persons, but there were no significant differences in age, gender, presence of extrapulmonary disease, symptoms, or signs.
47. Abouya L, Coulibaly IM, Coulibaly D, Kassim S, Ackah A, Greenber AE, Wiktor SZ, De Cock KM: Radiologic manifestations of pulmonary tuberculosis in HIV-1 and HIV-2-infected patients in Abidjan, Cote d'Ivoire. Tuber Lung Dis 1995, 76:436-440.
48. Post FA, Wood R, Pillay GP: Pulmonary tuberculosis in HIV infection: radiographic appearance is related to CD4+ T-lymphocyte count. Tuber Lung Dis 1995, 76:518-521.
49. Leung AN, Brauner MW, Gamsu G, Milka-Cabanne N, Romdhane HB, Carette M-F, Grenier P: Pulmonary tuberculosis: comparison of CT findings in HIV-seropositive and HIV-seronegative patients. Radiology 1996, 198:687-691. A retrospective comparison of computed tomography and conventional radiographic findings was performed between 42 HIV-seropositive and 42 HIV-seronegative patients with pulmonary tuberculosis. Intrathoracic adenopathy was significantly more common in the HIV-infected group on plain radiographs, but not on computed tomography. HIV-infected patients had a lower prevalence of consolidation, cavitation, and postprimary pattern on the computed tomography scans and a higher prevalence of miliary and extrapulmonary disease. Nodular opacities measuring 1 to 5 mm in diameter were the most common findings in both groups.
50. Kassim S, Sassan-Morokro M, Ackah A, Abouya LY, Digbeu H, Yesso G, Coulibaly I-M, Coulibaly D, Whitaker PJ, Doorly R, Vetter KM, Brattegaard K, Gnaore E, Greenberg AE, Wiktor SZ, De Cock KM: Two-year follow-up of persons with HIV-1 and HIV-2-associated pulmonary tuberculosis treated with short-course chemotherapy in West Africa. AIDS 1995, 9:1185-1191.
51. Asch S, Knowles L, Anup R, Jones BE, Pogoda J, Barnes PF: Relationship of isoniazid resistance to human immunodeficiency virus infection in patients with tuberculosis. Am J Respir Crit Care Med 1996, 153:1708-1710.
52. Lutfey M, Della-Latta P, Kapur V, Palumbo LA, Gurner D, Stotzky G, Brudney K, Dobkin J, Moss A, Musser JM, Kreiswirth BN: Independent origin of mono-rifampin-resistant Mycobacterium tuberculosis in patients with AIDS. Am J Respir Crit Care Med 1996, 153:837-840.
53. Frieden TR, Sherman LF, Maw KL, Fujiwara PI, Crawford JT, Nivin B, Sharp V, Hewlett D, Brudney K, Alland D, Kreiswirth BN: A multi-institutional outbreak of highly drug-resistant tuberculosis-epidemiology and clinical outcomes. JAMA 1996, 276:1229-1235. Using drug susceptibility and restriction fragment length polymorphism analyses, an outbreak of a strain of tuberculosis that was predictably resistant to isoniazid, rifampin, ethambutol, streptomycin, kanamycin, rifabutin, and usually ethionamide accounted for nearly one-fourth of the cases of multidrug-resistant tuberculosis in the United States during a 43 month period. Infection was associated with a high mortality, but patients treated with drugs to which the isolates were susceptible showed improved survival.
54. Cauthen GM, Dooley SW, Onorato IM, Ihle WW, Burr JM, Bigler WJ, Witte J, Castro: Transmission of Mycobacterium tuberculosis from tuberculosis patients with HIV infection or AIDS. Am J Epidemiol 1996, 144:69-77. An epidemiologic analysis of tuberculin skin test results in 3253 contacts of patients with tuberculosis in Dade County, Florida concluded that the risk of transmission from HIV-negative patients was significantly higher than from HIV-infected patients, even after adjusting for characteristics known to affect transmission.
55. Whalen C, Okwera A, Johnson J, Vjecha M, Hom D, Wallis R, Huebner R, Mugerwa R, Ellner J, and the Makerere University-Case Western Reserve University Research Collaboration: Predictors of survival in human immunodeficiency virus-infected patients with pulmonary tuberculosis. Am J Respir Crit Care Med 1996, 153:1977-1981. Four independent predictors of mortality were identified in 191 Ugandan HIV-infected patients with tuberculosis: anergy to purified protein derivative, atypical chest radiographic patterns, previous HIV-associated condition, and lymphopenia.
56. Shafer RW, Bloch AB, Larkin C, Vasudavan V, Seligman S, Dehovitz JD, DiFerdinando G, Stoneburner R, Cauthen G: Predictors of survival in HIV-infected tuberculosis patients. AIDS 1996, 10:269-272. Of fifty-four HIV-infected patients with newly diagnosed tuberculosis and without a prior AIDS-defining diagnosis, 84% died a median of 15 months after diagnosis (range, 1 to 80 months). Intrathoracic adenopathy, oral candidiasis, and reduced CD4 count were associated with decreased survival. CD4 count was the only independent predictor of survival.
57. Perneger TV, Sudre P, Lundgren JD, Hirschel B, for the AIDS in Europe Study Group: Does the onset of tuberculosis in AIDS predict shorter survival? Results of a cohort study in 17 European countries over 13 years. BMJ 1995, 311:1468-1471.
58. Goletti D, Weissman D, Jackson RW, Graham NM, Vlahov D, Klein RS, Munsiff SS, Ortona L, Cauda R, Fauci AS: Effect of Mycobacterium tuberculosis on HIV replication: role of immune activation. J Immunol 1996, 157:1271-1278. A five- to 160-fold increase in HIV viral replication was found in persons with acute tuberculosis.
59. Pablos-Mendez A, Sterling TR, Frieden TR: The relationship between delayed or incomplete treatment and all-cause mortality in patients with tuberculosis. JAMA 1996, 276:1223-1228.
60. Rodriguez-Barradas MC, Stool E, Musher DM, Gathe J Jr, Goldstein J, Genta RM, Yoffe B: Diagnosing and treating cytomegalovirus pneumonia in patients with AIDS. Clin Infect Dis 1996, 23:76-81.
61. Herry I, Cadranel J, Antoine M, Meharzi J, Michelson S, Parrot A, Rozenbaum W, Mayaud C: Cytomegalovirus-induced alveolar hemorrhage in patients with AIDS: a new clinical entity? Clin Infect Dis 1996, 22:616-620.
62. Dore GJ, Marriot DJ, Duflou JA: Clinico-pathological study of cytomegalovirus (CMV) in AIDS autopsies: under-recognition of CMV pneumonitis and CMV adrenalitis. Aust NZ J Med 1995, 25:503-506.
63. Meyohas M-C, Roux P, Bollens D, Chouaid C, Rozenbaum W, Meynard J-L, Poirot J-L, Frottier J, Mayaud C: Pulmonary cryptoccocosis: localized and disseminated infections in 27 patients with AIDS. Clin Infect Dis 1995, 21:628-633.
64. Miller KD, Mican JAM, Davey RT: Asymptomatic solitary pulmonary nodules due to Cryptococcus neoformans in patients infected with human immunodeficiency virus. Clin Infect Dis 1996, 23:810-812.
65. Torre D, Martegani R, Speranza F, Zeroli C, Fiori GP: Pulmonary cryptococcosis presenting as pneumothorax in a patient with AIDS. Clin Infect Dis 1995, 21:1524-1525.
66. Klein NC, Cunha RB: New antifungal drugs for pulmonary mycoses. Chest 1996, 110:525-532. Excellent review of the spectrum and clinical application of the available antifungal agents.
67. Trapnell CB, Narang PK, Li R, Lavelle JP: Increased plasma rifabutin levels with concomitant fluconazole therapy in HIV-infected patients. Ann Intern Med 1996, 124:573-576.
68. Parenti DM, Symingtion JS, Keiser J, Simon GL: Mycobacterium kansasii bacteremia in patients infected with human immunodeficiency virus. Clin Infect Dis 1995, 21:1001-1003.
69. Huang L, Schnapp LM, Gruden JF, Hopewell PC, Stansell JD: Presentation of AIDS-related pulmonary Kaposi's sarcoma diagnosed by bronchoscopy. Am J Respir Crit Care Med 1996, 153:1385-1390. The clinical and radiographic presentations of pulmonary Kaposi's sarcoma were reviewed in patients who were diagnosed using bronchoscopy. Cough, dyspnea, and fever were the most frequent symptoms, and bronchial wall thickening, nodules, Kerley B lines, and pleural effusions were common radiographic findings.
70. Khalil AM, Carette MF, Cadranel JL, Mayaud CM, Bigot JM: Intrathoracic Kaposi's sarcoma CT findings. Chest 1995, 108:1622-1626.
71. Griffiths MH, Miller RF, Semple SJG: Interstitial pneumonitis in patients infected with human immunodeficiency virus. Thorax 1995, 50:1141-1146. The clinical, radiographic, and pathologic findings of nonspecific interstitial pneumonitis are reviewed in seven HIV-infected patients. They all had dyspnea, with or without cough, and diffuse bilateral reticular opacities. Generally, the course was subacute, improving in six patients, half of whom were treated with corticosteroids.
72. Morse JH, Barst RJ, Itescu S, Flaster ER, Sinha G, Zhang Y, Fotino M: Primary pulmonary hypertension in HIV infection: an outcome determined by particular HLA class II alleles. Am J Respir Crit Care Med 1996, 153:1299-1301.
73. Eisner MD, Kaplan LD, Herndier B, Stulbarg MS: The pulmonary manifestations of AIDS-related non-Hodgkin's lymphoma. Chest 1996, 110:729-736.